---
title: "Autobio released its first-quarter performance, with a net profit attributable to the parent company of 270 million yuan, a year-on-year decrease of 16.76%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236376070.md"
description: "According to the Zhitong Finance APP, Autobio disclosed its first-quarter report for 2025, showing that the company achieved revenue of 996 million yuan, a year-on-year decrease of 8.56%; net profit attributable to the parent company was 270 million yuan, a year-on-year decrease of 16.76%; and net profit excluding non-recurring gains and losses was 257 million yuan, a year-on-year decrease of 18.19%. The basic earnings per share were 0.47 yuan"
datetime: "2025-04-17T09:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236376070.md)
  - [en](https://longbridge.com/en/news/236376070.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236376070.md)
generator: "portal-rs"
---

# Autobio released its first-quarter performance, with a net profit attributable to the parent company of 270 million yuan, a year-on-year decrease of 16.76%

According to the Zhitong Finance APP, Autobio (603658.SH) disclosed its first-quarter report for 2025, showing that the company achieved revenue of 996 million yuan, a year-on-year decrease of 8.56%; net profit attributable to the parent company was 270 million yuan, a year-on-year decrease of 16.76%; and net profit excluding non-recurring gains and losses was 257 million yuan, a year-on-year decrease of 18.19%. Basic earnings per share were 0.47 yuan

### Related Stocks

- [603658.CN](https://longbridge.com/en/quote/603658.CN.md)

## Related News & Research

- [RemeGen files board, board committee member list with disclosure responsibilities](https://longbridge.com/en/news/296803857.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [08:36 ETUltimate Men's HQ Launches Private Product-Match Education Experience](https://longbridge.com/en/news/296789283.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea](https://longbridge.com/en/news/296784834.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**